| Name | Relationship | Address | Signature | Signature date | CIK |
|---|---|---|---|---|---|
| Rosenblum Mark J | Exec VP Finance, CFO | C/O SALARIUS PHARMACEUTICALS, INC., 2450 HOLCOMBE BLVD., SUITE X, HOUSTON | /s/ Mark J. Rosenblum | 20 Nov 2025 | 0001329154 |
| Type | Sym | Class | Transaction | Value $ | Shares | Change % | * Price $ | Shares After | Date | Ownership | Footnotes |
|---|---|---|---|---|---|---|---|---|---|---|---|
| transaction | SLRX | Common Stock | Purchase | $16K | +20K | +11299.44% | $0.80 | 20.2K | 20 Nov 2025 | Direct | F1, F2 |
| Id | Content |
|---|---|
| F1 | Shares beneficially owned following the transaction is adjusted to reflect the reverse stock splits effective on June 16, 2024 and August 17, 2025. |
| F2 | Includes 20 shares of unvested restricted stock granted on January 3, 2023. |